Synchronous metastatic renal cell carcinoma (mRCC) treated with nivolumab and ipilimumab (N plus I) and the primary tumour (PT) in place

被引：2
|
作者：
Meerveld-Eggink, A. [1 ]
Graafland, N. [2 ]
Wilgenhof, S. [1 ]
Van Thienen, J. V. [1 ]
Grant, M. [3 ]
Szabados, B. E. [4 ]
Abu-Ghanem, Y. [5 ]
Boleti, E. [6 ]
Blank, C. U. [1 ]
Haanen, J. B. A. G. [1 ]
Powles, T. B. [7 ]
Bex, A. [8 ]
机构：
[1] Antoni van Leeuwenhoek Hosp NKI AVL, Dept Med Oncol, Netherlands Canc Inst, Amsterdam, Netherlands
[2] Netherlands Canc Inst, Urol, Amsterdam, Netherlands
[3] Queen Mary Univ London, Med Oncol, Barts Canc Inst, London, England
[4] Barts Canc Inst, Dept Med Oncol, London, England
[5] Royal Free London NHS Fdn Trust, Urol, London, England
[6] Royal Free Hosp, Acad Oncol Dept, Sch Med, London, England
[7] St Bartholomews Hosp, Oncol, London, England
[8] Antoni van Leeuwenhoek Hosp NKI AVL, Netherlands Canc Inst, Surg Oncol Urol Dept, Amsterdam, Netherlands
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.809
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
737P
引用
收藏
页码：S575 / S575
页数：1
相关论文
共 50 条
  • [41] Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab
    Brown, Landon C.
    Desai, Kunal
    Wei, Wei
    Kinsey, Emily N.
    Kao, Chester
    George, Daniel J.
    Rini, Brian, I
    Ornstein, Moshe C.
    Zhang, Tian
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (09)
  • [42] Combination nivolumab and ipilimumab with and without camu camu in first-line treatment of metastatic renal cell carcinoma (mRCC).
    Barragan-Carrillo, Regina
    Chawla, Neal Shiv
    Salgia, Nicholas
    Meza, Luis A.
    Zengin, Zeynep Busra
    Li, Xiaochen
    Dizman, Nazli
    Ebrahimi, Hedyeh
    Hsu, Joann
    Castro, Daniela V.
    Mercier, Benjamin D.
    Dorff, Tanya B.
    Tripathi, Abhishek
    Bergerot, Cristiane Decat
    Bergerot, Paulo Gustavo
    Chehrazi-Raffle, Alex
    Pal, Sumanta Kumar
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS491 - TPS491
  • [43] Real-world outcomes in patients with metastatic renal cell carcinoma treated with first-line nivolumab plus ipilimumab
    Doshi, Gurjyot K.
    Robert, Nicholas J.
    Chen, Liwei
    Chan, Philip K.
    Del Tejo, Viviana
    Stwalley, Brian
    Huo, Stephen
    Geynisman, Daniel M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (28)
  • [44] Association of lung immune prognostic index with survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
    Yamashita, Shimpei
    Hamamoto, Shuzo
    Furukawa, Junya
    Fujita, Kazutoshi
    Takahashi, Masayuki
    Miyake, Makito
    Ito, Noriyuki
    Iwamoto, Hideto
    Kohjimoto, Yasuo
    Hara, Isao
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 54 (06) : 722 - 729
  • [45] Association between immune-related adverse events and survival in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
    Hayase, T.
    Washino, S.
    Shirotake, S.
    Inoue, M.
    Kagawa, M.
    Takeshita, H.
    Miura, Y.
    Hyodo, Y.
    Izumi, K.
    Kawakami, S.
    Saito, K.
    Kageyama, Y.
    Oyama, M.
    Miyagawa, T.
    ANNALS OF ONCOLOGY, 2022, 33 : S1488 - S1489
  • [46] Clinical management and outcomes of patients with advanced renal cell carcinoma (aRCC) treated with nivolumab plus ipilimumab (N plus I): A real-world study
    Geldart, T. R.
    Pickering, L. M.
    Sharma, A.
    Scott, D.
    Parikh, O. A.
    Coleman, S.
    Dhokia, P.
    Hale, M.
    Vaz, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S1020 - S1020
  • [47] Healthcare resource utilization (HCRU) and costs for patients (pts) with metastatic renal cell carcinoma (mRCC) receiving first-line (LOT1) pembrolizumab plus axitinib (P plus A) or ipilimumab plus nivolumab (I plus N).
    Shah, Neil J.
    Shinde, Reshma
    Moore, Kristin
    Sainski-Nguyen, Amy
    Le, Lisa
    Cao, Feng
    Song, Rui
    Singhal, Puneet
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [48] Clinical activity, immune and molecular correlates of nivolumab vs. nivolumab plus bevacizumab vs nivolumab plus ipilimumab in metastatic renal cell carcinoma
    Gao, Jianjun
    Karam, Jose A.
    Wood, Christopher G.
    Matin, Surena
    Ahrar, Kamran
    Jonasch, Eric
    Tannir, Nizar
    Campell, Matthew
    Ng, Chaan S.
    Slack, Rebecca S.
    Rao, Priya
    Allison, James P.
    Blando, Jorge M.
    Vence, Luis M.
    Basu, Sreyashi
    Zhao, Hao
    Chen, Tenghui
    Chen, Hong
    Sharma, Padmanee
    CANCER RESEARCH, 2017, 77
  • [49] Clinical Activity of Ipilimumab Plus Nivolumab in Patients With Metastatic Non- Clear Cell Renal Cell Carcinoma
    Gupta, Ruby
    Ornstein, Moshe Chaim
    Li, Hong
    Allman, Kimberly D.
    Wood, Laura S.
    Gilligan, Timothy
    Garcia, Jorge A.
    Von Merveldt, Dendra
    Hammers, Hans J.
    Rini, Brian I.
    CLINICAL GENITOURINARY CANCER, 2020, 18 (06) : 429 - 435
  • [50] Distinct outcomes in Hispanic/Latinx and non-Hispanic/Latinx patients with metastatic renal cell carcinoma (mRCC) treated with first-line ipilimumab plus nivolumab (ipi/nivo).
    Ali, Sana
    Leong, Sally
    Meza, Luis A.
    Dizman, Nazli
    Zengin, Zeynep Busra
    Kim, Tane
    Pak, Youngju
    Onyshchenko, Mykola
    Pal, Sumanta K.
    Chehrazi-Raffle, Alex
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345